Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecopipam DDI with Itraconazole or Rifampicin
NCT06194864Phase 1Completed
- Sponsor
- Emalex Biosciences
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ecopipam in Tourette syndrome (TS) (2 arms), sponsored by Emalex Biosciences. Primary endpoints: Area under the concentration-time curve from time zero to infinity (AUC0-inf) of ecopipam, Area under the concentration-time curve from time zero to the last measurable concentration (AUC0-t) of ecopipam and 2 more. Started Jan 2024; status: completed.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT06194864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194864.